NEW YORK (GenomeWeb) – Exact Sciences reported after the close of the market on Tuesday that its third quarter revenues rose 63 percent year over year thanks to a 49 percent increase in testing volumes for its Cologuard colorectal cancer screening test.
For the three months ended Sept. 30, the Madison, Wisconsin-based molecular diagnostics company reported revenues of $118.3 million, up from revenues of $72.6 million a year earlier and beating the analysts' average estimate of $109.3 million.